JCO3 Rec'd PCT/PTO 0 6 MAY 2005 TO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 5141N1P1

U.S. APPLICATION

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2003/036003 10 November 2003 (10.11.2003) 12 November 2002 (12.11.2002)

TITLE OF INVENTION Indolyl Pyrazinone Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis									
APPLICANT(S) FOR DO/EO/US									
Gaetan H. Ladouceur, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information	n:								
1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.									
2. L.J This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.									
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
The US has been elected (Article 31).									
A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
a. is attached hereto (required only if not communicated by the International Bureau).									
b. has been communicated by the International Bureau.									
c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
a. is attached hereto.									
b. has been previously submitted under 35 U.S.C. 154(d)(4).									
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))									
a. are attached hereto (required only if not communicated by the International Bureau).									
b. have been communicated by the International Bureau.									
c. have not been made; however, the time limit for making such amendments has NOT expired.									
d. have not been made and will not be made.									
An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).									
An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).									
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).									
Items 11 to 20 below concern document(s) or information included:									
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. A preliminary amendment.									
An Application Data Sheet under 37 CFR 1.76.									
15. A substitute specification.									
16. A power of attorney and/or change of address letter.									
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.									
A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
20 X Other items or information: 1) Certificate of Mailing under 37 C.F.R. 1.10; and									

Other items or information: 2) Itemized Return Receipt Postcard.

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ORIGINAL

Date of Deposit: 6 May 2305 Express Mail Label No.: ED 168 598 443 US

JC14 Rec'd PCT/PTO 06 MAY 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER			
U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. PCT/US2003/036003						5141N1P1			
21. The following fees are submitted:							Applicant use	Office use only	
a) Basic national fee\$300.00							\$ 300.00	<u></u>	
b) Examination fee\$200.00						\$ 200.00			
X c) Search fee\$500.00							\$ 500.00	· · · · · · · · · · · · · · · · · · ·	
TOTAL OF ABOVE CALCULATIONS = \$1000.00							\$ 1,000.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	eets Extra sheets		Number of each additional 50 or fraction thereof (round up to a whole number)			RATE			
214 - 100 =	=	114 /50 =		3		× \$250.00	\$ 750.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).							\$		
CLAIMS	CLAIMS NUMBER FIL		LED NUMBER EXTRA RATE			RATE	\$		
Total claim	าร	14	14 - 20 = 0		×	\$50.00	\$ 00.00		
Independent claims		4	- 3 =	1	×	\$200.00	\$ 200.00		
MULTIPLE DE	PENDEN	T CLAIM(S) (if a	pplicable)	0	+	\$360.00	\$ 00.00		
TOTAL OF ABOVE CALCULATIONS =							\$ 1,950.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.							\$		
SUBTOTAL =							\$ 1,950.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$		
TOTAL NATIONAL FEE =							\$ 1,950.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +							\$		
TOTAL FEES ENCLOSED =							\$ 1,950.00		
Amount to be refunded:								\$	
Amount to be charged								\$	
a. A che	eck in the	amount of \$		to cover the abo	ve fee	s is enclosed.			
b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 1,950.00 to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3372</u> . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
		NDENCE TO:				/			
) (:1)	Fhr					
Jeffrey M. Greenman Bayer Pharmaceuticals Corporation SIGNATUR							The street of th		
400 Morgan Lane William						William F. C	Gray l		
West Haver	n, CT 06	516				NAME			
						31,018			
REGISTRAT							ION NUMBER		

Attorney's Docket No. 5141N1P1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gaetan H. Ladouceur, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/US2003/036003

Filed: herewith

For: Indolyl Pyrazinone Derivatives Useful for Treating Hyper-Proliferative Disorders and

Diseases Associated with Angiogenesis

I hereby certify that the attached correspondence comprising:

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

X Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE]; × Application Data Sheet under 37 C.F.R. 1.76; \Box Preliminary Amendment; " Original Declaration of Copy of oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)); Inventorship was filed with the X **PCT Request on 10 November** English Translation of the Application (35 U.S.C. 371(c)(2)); 2003 ** \mathbf{x} Copy of the International Application as filed (35 U.S.C. 371(c)(2)); Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information

Return Receipt Post Card;

Other: Forms PCT/IB/306 notifying the recording of the change of address of:

Gaetan H. Ladouceur, Brian Bear, Michael J. Burke, James Cook, Robert Sibley, and the change of nationality of Jacques Dumas

Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein;

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>ED168598443US</u> addressed to:

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

6 May 05

Signature of Person Certifying / William F. Gray